Sign in
Taking peopleNo phase

Probiotic Lactobacillus rhamnosus LRa05 for blood sugar in gestational diabetes

Tests the probiotic Lactobacillus rhamnosus LRa05 in pregnant women with gestational diabetes.

Key facts

Who runs it
Wecare Probiotics Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Efficacy of Lactobacillus Rhamnosus LRa05 in Gestational Diabetes
Status
Recruiting
People taking part
80 people, planned
Started
10 Apr 2025
Planned end
10 Mar 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Conventional treatment and Probiotic
Record updated
30 March 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for pregnant women with gestational diabetes (diabetes that starts in pregnancy). It tests the probiotic Lactobacillus rhamnosus LRa05 on blood sugar and gut bacteria.

Age
18 to 50 years
Sex
Pregnant women
Disease stage
Gestational diabetes found at 24 weeks of pregnancy by an abnormal sugar drink test (OGTT). Pregnancy with one baby, with no structural or chromosome problems found.
Earlier treatment
No probiotic-containing foods (such as yogurt, fermented foods, soybean paste) in the 2 weeks before the study. No recent use of products that work like the study product.
Biomarker or test result
OGTT with an 82.5g glucose load: fasting ≥ 5.1 mmol/L (92 mg/dL), 1-hour ≥ 10 mmol/L, or 2-hour ≥ 8.5 mmol/L (one or more).

Main reasons for not taking part

  • Long-term diseases such as immune deficiency, high blood pressure, diabetes, kidney or liver disease
  • Other hormone diseases, or medicines that affect blood sugar or blood fats
  • Severe heart, kidney, liver or gut diseases
  • Use of medicines that weaken the immune system
  • Allergy to probiotics or study product parts; smoking, drinking alcohol or drug abuse

This trial only enrols pregnant participants. The registry sentence this rests on: 2. Pregnant women aged 18 to 50 years.

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Women diagnosed with gestational diabetes mellitus (GDM) at 24 weeks of gestation; Diagnostic criteria for GDM: Abnormal oral glucose tolerance test (OGTT) with an 82.5g glucose load during the 24th week of pregnancy (defined as meeting one or more of the following plasma glucose thresholds: fasting ≥ 5.1 mmol/L, 1-hour ≥ 10 mmol/L, or 2-hour ≥ 8.5 mmol/L)
  • Pregnant women aged 18 to 50 years
  • Singleton pregnancy with a fetus confirmed to be structurally and chromosomally normal via ultrasound or other prenatal diagnostic methods
  • No history of chronic diseases, including immune deficiency, hypertension, diabetes, kidney disease, or liver disease
  • No consumption of probiotic-containing foods (e.g., yogurt, fermented foods, soybean paste) within the two weeks prior to the study
  • Willing and able to provide written informed consent
  • Capable of complying with the study protocol and follow-up requirements

Who cannot take part

  • Those with immunodeficiency diseases or currently using immunosuppressive agents
  • Those with unhealthy lifestyle habits, such as smoking, alcohol consumption, or drug abuse
  • Those with severe cardiovascular, kidney, or liver diseases
  • Those with severe gastrointestinal diseases that may affect the absorption or metabolism of probiotics
  • Those with a history of allergy to probiotics or any components of the study products
  • Those with other endocrine diseases or currently using medications that affect blood glucose control
  • Those currently using other medications that may affect blood glucose control or lipid levels
  • Those who have taken items with similar functions to the test product in the short term, which may affect the judgment of the results
  • Those who do not consume the test samples as required or do not follow up on time, resulting in uncertain efficacy
  • Study participants deemed unsuitable by other researchers

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 50 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to comprehensively evaluate the multifaceted impacts of Lactobacillus rhamnosus LRa05 on patients with gestational diabetes. Initially, the study will investigate the effects of LRa05 on improving patients' blood glucose levels and gut microbiota. Additionally, the study will assess the impact of this strain on patients' blood lipid levels, inflammatory markers, and body mass index (BMI). Furthermore, the study will also focus on its effects on thyroid function, vaginal microbiota, and bile acid metabolism in patients with gestational diabetes.

The 2 groups in the trial

  • Probiotic GroupTreatment being tested

    Participants will follow a controlled diet and exercise regimen, while also consuming the probiotic Lactobacillus rhamnosus LRa05 at a dosage of one stick per day (each stick contains 3 grams with 30 billion CFU), continuing until delivery.

    Treatment: Conventional treatment and Probiotic

  • Placebo GroupNo study treatment, for comparison

    Participants will only receive standard treatment (diet control and exercise therapy) until delivery.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessing the Efficacy of Lactobacillus Rhamnosus LRa05 in Improving Blood Glucose and Gut Microbiota in Patients With Gestational Diabetes
Plain-language title
Probiotic Lactobacillus rhamnosus LRa05 for blood sugar in gestational diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06901791, who can take part
Record updated
30 March 2025